Can Alcon turn baseball fandom into a growth engine for Systane in Canada’s dry eye category?
See how Alcon is using the Toronto Blue Jays to expand Systane’s dry eye reach in Canada and what it means for eye care competition.
Pharma & Biotech
Pharma & Biotech
Acadia Pharmaceuticals broadens Rett syndrome treatment flexibility with DAYBUE STIX rollout in the United States
Acadia Pharmaceuticals has launched DAYBUE STIX for Rett syndrome in the U.S. Read what this means for adoption, tolerability, and market strategy.
Pharma & Biotech
Parnell expands U.S. manufacturing footprint with Noble Pharma acquisition amid supply continuity pressures
Parnell’s Noble Pharma acquisition expands U.S. veterinary drug manufacturing capacity. Read what it could change for supply, scale, and market strategy.
Pharma & Biotech
Why Meiji Seika Pharma is using Singapore to scale its ASEAN vaccine and pharma strategy
Meiji Seika Pharma has launched Meiji Pharma Asia in Singapore. Read what this ASEAN expansion could change for vaccines and regional pharma growth.
Pharma & Biotech
Why the latest Merakris Therapeutics data may sharpen industry focus on refractory wound healing
Read why Merakris Therapeutics’ MTX-001 data may sharpen industry focus on refractory wound healing and reshape the late-stage wound care outlook.
Pharma & Biotech
Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears
electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.
Pharma & Biotech
Why Inhibikase Therapeutics’ pivotal PAH study may become a major 2026 biotech catalyst
Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.
Pharma & Biotech
Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?
Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.
Pharma & Biotech
Why Anixa Biosciences’ Phase 2 breast cancer vaccine push matters more than the manufacturing deal itself
Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers.
Pharma & Biotech
Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.